Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions β€” written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Reviparin

Introduction

Overview

Overview

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins.

Pharmacodynamic

Pharmacodynamic

Reviparin is a low molecular weight heparin (LMWH) obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-Ξ±-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.

Indications

Indications

  • Prophylaxis of deep vein thrombosis (DVT)
  • Prophylaxis of perioperative thromboembolism[1][2]
  • Treatment of DVT with or without pulmonary embolism (PE)[3]
  • Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)[4][5]
References

References

  1. ↑ Kakkar VV, Cohen AT, Mohamed MS (1996). “Patients at risk of venous thromboembolism–clinical results with reviparin”. Thromb. Res. 81 (2 Suppl): S39–45. PMIDΒ 8822126. |access-date= requires |url= (help)
  2. ↑ Lassen MR, Backs S, Borris LC, Kaltoft-SΓΈrenson M, Coff-Ganes H, Jeppesen E (1999). “Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery”. Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMIDΒ 10549720. |access-date= requires |url= (help)
  3. ↑ Gore M, Kelkar P, Rege N, Ross C (October 2004). “Reviparin sodium clivarine: a review of its therapeutic use”. J Indian Med Assoc. 102 (10): 589–90, 592. PMIDΒ 15887830. |access-date= requires |url= (help)
  4. ↑ Preisack MB, Karsch KR (December 1993). “Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty”. Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMIDΒ 8180331. |access-date= requires |url= (help)
  5. ↑ Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). “Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation”. J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. PMIDΒ 8917255. Retrieved 2014-09-18.
External links
  • reviparin at the US National Library of Medicine Medical Subject Headings (MeSH)
  • Yusuf S, Mehta SR, Xie C; et al. (2005). “Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation”. JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMIDΒ 15671427.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]